
Comparative effectiveness of exercise, antidepressants, and their combination in treating non-severe depression: A systematic review and network metaanalysis of randomized controlled trials


Supplementary Online Content


- eFigure 1. PRISMA flow chart
- eFigure 2. Risk of bias contributions
- eFigure 3. Indirectness contributions
- eTable 1. Distribution of study characteristics
- eTable 2. Meta-regression for direct comparisons
- eTable 3. Risk of bias for all studies
- eTable 4. Indirectness for all studies
- eTable 5. Confidence in Network Meta-analysis (CINeMA) final report
- eTable 6. Treatment ranking based on the P-score
- eTable 7. Assessment of inconsistency within comparisons
- eTable 8. Sensitivity analyses
- eAppendix 1. Search strategy
- eAppendix 2. Additional methodology information
- eAppendix 3. Pairwise meta-analyses
- eAppendix 4. References


eFigure 1. PRISMA flow chart




2









eTable 1. Distribution of study characteristics

Comparison	N studies	Participant age (years)	Sex (% women)	Intervention duration (weeks)	Outcome measure
EX:AD	3	< 60	≥ 50%	19	HAM-D
AD:CT	11	< 60	≥ 50%	9	HAM-D
EX:CT	6	< 60	≥ 50%	10	HAM-D
EX+AD:AD	4	< 60	≥ 50%	11	HAM-D
EX+AD:EX	1	< 60	≥ 50%	16	HAM-D

eTable 2. Meta-regression for direct comparisons

Comparison ^a	Ν	Coefficient [95% CI]	SE	P value
EX:AD	3			
- Mean age		-0.00 [-0.16 to 0.16]	0.01	0.94
- Mean duration		-0.01 [-0.21 to 0.20]	0.02	0.75
 Proportion of women 		-0.02 [-0.39 to 0.36]	0.03	0.67
- Outcome measure		-0.05 [-1.68 to 1.58]	0.13	0.75
AD:CT	11			
- Mean age		0.01 [-0.03 to 0.05]	0.02	0.70
- Mean duration		0.02 [-0.03 to 0.08]	0.02	0.35
 Proportion of women 		-0.01 [-0.03 to 0.01]	0.01	0.40
 Outcome measure^b 		NA	NA	NA
EX:CT	6			
- Mean age		0.03 [-0.03 to 0.08]	0.02	0.20
 Mean duration 		0.08 [-0.08 to 0.25]	0.06	0.22
 Proportion of women 		0.00 [-0.04 to 0.04]	0.01	0.92
 Outcome measure 		0.63 [-0.48 to 1.74]	0.40	0.19
EX+AD:AD	4			
- Mean age		0.01 [-0.06 to 0.09]	0.02	0.54
- Mean duration		0.04 [-0.09 to 0.18]	0.03	0.28
 Proportion of women 		-0.05 [-0.36 to 0.27]	0.07	0.58
- Outcome measure		-0.49 [-2.03 to 1.06]	0.36	0.31

^aMeta-regression for the EX+AD:EX comparison could not be performed because only one study was available for that comparison

^bMeta-regression for this categorical outcome could not be performed because all studies within this comparison used the same outcome measure

eTable 3. Risk of bias for all studies

Study	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	RoB
Bjerkenstedt et al., 2004	Low	Low	Low	Low	Some concerns	Some concerns
Blumenthal et al., 1999	Some concerns	Low	Low	Some concerns	Some concerns	Some concerns
Blumenthal et al., 2007	Low	Low	Low	Low	Low	Low
Danielsson et al., 2014	Low	Low	Low	Low	Some concerns	Some concerns
Detke et al., 2002	Some concerns	Low	Low	Low	Low	Some concerns
Detke et al., 2004	Some concerns	Low	Low	Low	Low	Some concerns
Dunn et al., 2005	Low	Low	Low	Low	Low	Low
Fava et al., 2005	Some concerns	Low	Low	Low	Some concerns	Some concerns
Gastpar et al., 2005	Some concerns	Low	Low	Low	Some concerns	Some concerns
Goldstein et al., 2004	Low	Low	Low	Low	Low	Low
Hemat-Far et al., 2012	Some concerns	Some concerns	Low	Some concerns	Some concerns	Some concerns
Hidalgo et al., 2021	Some concerns	Low	Low	Some concerns	Low	Some concerns
Krogh et al., 2012	Some concerns	High	Low	Low	Low	High
Mao et al., 2015	Low	Low	Low	Low	Low	Low
Mather et al., 2002	Low	Some concerns	Low	Low	Some concerns	Some concerns
McNeil et al., 1991	Some concerns	Some concerns	Low	Some concerns	Some concerns	Some concerns
Moreno et al., 2005	Low	Low	Low	Low	Low	Low
Perahia et al., 2006	Some concerns	Low	Low	Low	Low	Some concerns
Philipp et al., 1999	Some concerns	Low	Low	Low	Some concerns	Some concerns
Sadeghi et al., 2016	Some concerns	Low	Some concerns	Low	Low	Some concerns
Siqueira et al., 2016	Some concerns	Low	Low	Low	Low	Some concerns

eTable 4. Indirectness for all studies

Author	Population		Intervention		Outcome		Comparisons	Indirectness
Bjerkenstedt et al., 2005	Low		Low		Low		High	Moderate
Blumenthal et al., 1999	Low		Low		Low		Low	Low
Blumenthal et al., 2007	Low		Low		Low		Low	Low
Danielsson et al., 2014	Low		Low		Low		Low	Low
Detke et al., 2002	Low		Low		Low		High	Moderate
Detke et al., 2004	Low		Low		Low		High	Moderate
Dunn et al., 2005	Low		Low		Low		High	Moderate
Fava et al., 2005	Low		Low		Low		High	Moderate
Gastpar et al., 2006	Low		Low		Low		High	Moderate
Goldstein et al., 2004	Low		Low		Low		High	Moderate
Hemat-Far et al., 2012	High	Female students	Low		Moderate	Self-reported questionnaire	High	High
Hidalgo et al. 2021	High	Elderly	Low		Low	·	Low	Moderate
Krogh et al., 2012	Low		Low		Low		High	Moderate
Mao et al., 2015	Low		Low		Low		High	Moderate
Mather et al., 2002	Low		Low		Low		Low	Low
McNeil et al., 1991	High	Elderly	Moderate	Somewhat different	Moderate	Self-reported questionnaire	High	High
Moreno et al., 2006	Low		Low		Low	·	High	Moderate
Perahia et al., 2006	Low		Low		Low		High	Moderate
Philipp et al., 1999	Low		Low		Low		High	Moderate
Sadeghi et al., 2016	Low		Low		Moderate	Self-reported questionnaire	High	Moderate
Siqueira et al., 2016	Low		Low		Low		Low	Low

8

Comparison	Ν	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
AD:CT	10	Some concerns	Some concerns	Some concerns	No concerns	Some concerns	No concerns	Moderate
AD:EX	2	Some concerns	Some concerns	Some concerns	Some concerns	No concerns	No concerns	Moderate
EX+AD:AD	5	Some concerns	Some concerns	No concerns	Some concerns	No concerns	No concerns	High
EX:CT	6	Some concerns	Some concerns	Some concerns	No concerns	Some concerns	No concerns	Moderate
EX+AD:EX	1	Some concerns	Some concerns	No concerns	Some concerns	Some concerns	No concerns	Moderate
EX+AD:CT	0	Some concerns	Some concerns	Some concerns	No concerns	No concerns	No concerns	High

eTable 5. Confidence in Network Meta-analysis (CINeMA) final report

eTable 6. Treatment ranking based on the P-score

Treatment	P-score
EX	0.7865
EX+AD	0.7639
AD	0.4489
СТ	0.0008

Comparison	k	Direct	Indirect	Difference	z	P-value
AD:CT	11	-0.33	-0.38	0.05	0.22	0.83
AD:EX	3	0.07	0.19	-0.12	-0.52	0.60
EX+AD:AD	4	0.12	0.09	0.03	0.06	0.95
EX:CT	6	-0.43	-0.48	0.05	0.21	0.83
EX+AD:CT	0	NA	-0.45	NA	NA	NA
EX+AD:EX	1	-0.18	0.12	-0.30	-0.89	0.38

eTable 7. Assessment of inconsistency within comparisons

AD: Antidepressants; CT: Control; EX: Exercise; NA: Not available

eTable 8. Sensitivity analyses

Reasons for exclusion	N	EX-AD	Comb-AD	Comb-EX	Comb-CT	EX-CT	AD-CT	l ²
All included	21	12 (33 to .10)	12 (40 to .16)	00 (33 to .33)	45 (76 to14)	45 (67 to23)	33 (48 to19)	46.2%
Participants older than 60	19	10 (37 to .16)	12 (41 to .17)	02 (37 to .34)	44 (76 to12)	43 (69 to17)	33 (48 to18)	49.0%
High Risk of Bias	20	20 (40 to .00)	13 (38 to .13)	.07 (23 to .37)	48 (77 to20)	56 (77 to34)	36 (49 to23)	31.0%
High Indirectness	19	07 (29 to .15)	11 (39 to .17)	04 (36 to .29)	43 (74 to12)	39 (62 to16)	32 (46 to18)	46.9%
Intervention longer than 12 weeks	18	18 (58 to .21)	29 (67 to .09)	11 (65 to .44)	63 (-1.05 to22)	53 (88 to17)	35 (52 to17)	52.5%
SD imputed	16	17 (42 to .09)	14 (45 to .18)	03 (34 to .40)	41 (78 to04)	44 (70 to 0.19)	28 (50 to .05)	50.4%
Attention/active control comparison	17	14 (35 to .07)	09 (39 to .21)	05 (28 to .38)	44 (76 to11)	48 (71 to25)	34 (47 to22)	32.6%
Passive control comparison	19	07 (29 to .15)	11 (39 to .17)	04 (36 to .29)	43 (74 to12)	39 (62 to16)	32 (46 to18)	46.9%

eAppendix 1. Search strategy

PubMed

Search	Query
#1	Bupropion[MeSH Terms] OR bupropion[Title/Abstract] OR 34911-55-2[EC/RN Number]
#2	Citalopram[MeSH Terms] OR citalopram[Title/Abstract] OR 59729-33-8[EC/RN Number]
#3	escitalopram[Title/Abstract] OR 128196-01-0[EC/RN Number]
#4	desvenlafaxine[Title/Abstract] OR 386750-22-7[EC/RN Number]
#5	Fluoxetine[MeSH Terms] OR fluoxetine[Title/Abstract] OR 54910-89-3[EC/RN Number]
#6	Fluvoxamine[MeSH Terms] OR fluvoxamine[Title/Abstract] OR 54739-18-3[EC/RN Number]
#7	Milnacipran[Supplementary Concept] OR milnacipran[Title/Abstract] OR levomilnacipran[Title/Abstract]
#8	Mirtazapine[Supplementary Concept] OR mirtazapine[Title/Abstract] OR 4685R51V7M[EC/RN Number]
#9	Nefazodone[Supplementary Concept] OR nefazodone[Title/Abstract]
#10	Paroxetine[MeSH Terms] OR paroxetine[Title/Abstract] OR 61869-08-7[EC/RN Number]
#11	Sertraline[MeSH Terms] OR sertraline[Title/Abstract] OR 79617-96-2[EC/RN Number]
#12	Trazodone[MeSH Terms] OR trazodone[Title/Abstract] OR 19794-93-5[EC/RN Number]
#13	venlafaxine[Title/Abstract] OR 99300-78-4[EC/RN Number]
#14	vilazodone[Title/Abstract] OR 163521-08-2[EC/RN Number]
#15	Vortioxetine[Supplementary Concept] OR vortioxetine[Title/Abstract] OR TKS641KOAY[EC/RN Number]
#16	duloxetine[Title/Abstract] OR 116539-58-3[EC/RN Number]
#17	Antidepressive Agents, Second Generation[MeSH Terms] OR Antidepressive Agents, Second-Generation[Pharmacological Action] OR antidepress*[Title/Abstract]
#18	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17
#19	Depression, unipolar[MeSH Terms] OR Depressive disorders[MeSH Terms] OR depress*[Title/Abstract]
#20	Randomized controlled trial[MeSH Terms] OR Random allocation[MeSH Terms] OR (random*[Title/Abstract] AND (control*[Title/Abstract] OR placebo[Title/Abstract]))
#21	#18 AND #19 AND #20
#22	Exercise[MeSH Terms] OR exercise[Title/Abstract] OR "physical activity"[Title/Abstract] OR aerobic[Title/Abstract] OR training[Title/Abstract] OR lift*[Title/Abstract] OR running[Title/Abstract] OR walk*[Title/Abstract] OR jogging[Title/Abstract] OR swim*[Title/Abstract] OR cycl*[Title/Abstract]
#23	#19 AND #20 AND #22
#24	Adults[MeSH Terms] OR adult*[Title/Abstract]
#25	#21 AND #24
#26	#23 AND #24
#27	#25 OR #26
#28	Filters: Chinese, English, Italian, from 1990 - 3000/12/12

PsycInfo

Search	Query
S1	SU(bupropion) OR AB(bupropion) OR TI(bupropion)

S2	SU(citalopram) OR AB(citalopram) OR TI(citalopram)
S3	SU(escitalopram) OR AB(escitalopram) OR TI(escitalopram)
S4	SU(Desvenlafaxine) OR AB(Desvenlafaxine) OR TI(Desvenlafaxine)
S5	SU(Fluoxetine) OR AB(Fluoxetine) OR TI(Fluoxetine)
S6	SU(Fluvoxamine) OR AB(Fluvoxamine) OR TI(Fluvoxamine)
S7	SU(Levomilnacipran) OR AB(Levomilnacipran) OR TI(Levomilnacipran)
S8	SU(mirtazapine) OR AB(mirtazapine) OR TI(mirtazapine)
S9	SU(Nefazodone) OR AB(Nefazodone) OR TI(Nefazodone)
S10	SU(Paroxetine) OR AB(Paroxetine) OR TI(Paroxetine)
S11	SU(Sertraline) OR AB(Sertraline) OR TI(Sertraline)
S12	SU(Trazodone) OR AB(Trazodone) OR TI(Trazodone)
S13	SU(Venlafaxine) OR AB(Venlafaxine) OR TI(Venlafaxine)
S14	SU(vilazodone) OR AB(vilazodone) OR TI(vilazodone)
S15	SU(vortioxetine) OR AB(vortioxetine) OR TI(vortioxetine)
S16	SU(duloxetine) OR AB(duloxetine) OR TI(duloxetine)
S17	SU(Antidepressive Drugs, Second-Generation) OR TI(antidepress*) OR AB(antidepress*)
S18	S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12
	OR S13 OR S14 OR S15 OR S16 OR S17
S19	SU(depression) OR SU(depressive disorder) OR TI(depress*) OR AB(depress*)
S20	SU(randomized controlled trial) OR SU(randomized clinical trial) OR SU(random
	allocation) OR TI(random* AND control*) OR AB(random* AND control*) OR TI(random*
	AND placebo) OR AB(random* AND placebo)
S21	S18 AND S19 AND S20
S22	SU(adults) OR TI(adult*) OR AB(adult*)
S23	S21 AND S22
S24	SU(exercise) OR TI(exercise) OR AB(exercise) OR SU(physical activity) OR TI(aerobic)
	OR AB(aerobic) OR TI(training) OR AB(training) OR TI(lift*) OR AB(lift*) OR SU(running)
	OR TI(running) OR AB(running) OR TI(jogging) OR AB(jogging) OR TI(walk*) OR
	AB(walk*) OR TI(swim*) OR AB(swim*) OR TI(cycl*) OR AB(cycl*)
S25	S19 AND S20 AND S24
S26	S22 AND S25
S27	S23 AND S26
S28	#27 Limit date range 1990-2021 AND Limit language: English, Chinese, Italian

Cochrane Library

ID	Search
#1	bupropion:ti,ab,kw OR [mh bupropion]
#2	citalopram:ti,ab,kw OR [mh citalopram]
#3	escitalopram:ti,ab,kw OR [mh escitalopram]
#4	desvenlafaxine:ti,ab,kw OR [mh desvenlafaxine]
#5	duloxetine:ti,ab,kw OR [mh duloxetine]
#6	fluoxetine:ti,ab,kw OR [mh fluoxetine]
#7	fluvoxamine:ti,ab,kw OR [mh fluvoxamine]
#8	Levomilnacipran:ti,ab,kw OR [mh levomilnacipran]
#9	mirtazapine:ti,ab,kw OR [mh mirtazapine]
#10	nefazodone:ti,ab,kw OR [mh nefazodone]
#11	Paroxetine:ti,ab,kw OR [mh paroxetine]
#12	sertraline:ti,ab,kw OR [mh sertraline]
#13	Trazodone:ti,ab,kw OR [mh trazodone]
#14	venlafaxine:ti,ab OR [mh venlafaxine]
#15	vilazodone:ti,ab,kw OR [mh vilazodone]
#16	vortioxetine:ti,ab,kw OR [mh duloxetine]

#17	[mh Antidepressive Agents, Second-Generation] OR antidepress*:ti,ab,kw
#18	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR 11 OR #12 OR
	#13 OR #14 OR #15 OR #16 OR #17
#19	[mh Depression] OR [mh Depressive Disorder, Major] OR depress*:ti,ab,kw
#20	[mh Randomized Controlled Trials as Topic] OR [mh Randomized Controlled Trial] OR
	[mh Random Allocation] OR ("randomized controlled"):ti,ab,kw OR ("controlled
	clinical"):ti,ab,kw
#21	#18 AND #19 AND #20
#22	[mh Adults] OR adults:ti,ab,kw
#23	#21 AND #22
#24	[mh Exercise] OR [mh "physical activity"] OR exercise:ti,ab,kw OR training:ti,ab,kw OR
	lift*:ti,ab,kw OR aerobic:ti,ab,kw OR running:ti,ab,kw OR walk*:ti,ab,kw OR
	jogging:ti,ab,kw OR swim*:ti,ab,kw OR cycl*:ti,ab,kw
#25	#19 AND #20 AND #24
#26	#25 AND #22
#27	#23 OR #26 with Publication Year from 1990 to 2021 AND language: English, Chinese,
	Italian

Embase

#	Searches
1	exp bupropion/ or bupropion.tn,ab,ti. or 34911 55 2.rn.
2	exp citalopram/ or citalopram.tn,ab,ti. or 59729 33 .rn.
3	exp escitalopram/ or escitalopram.tn,ab,ti. or 128196 01 0.rn.
4	exp desvenlafaxine/ or desvenlafaxine.tn,ab,ti. or 93413 62 8.rn.
1 2 3 4 5 6 7 8 9	exp fluoxetine/ or fluoxetine.tn,ab,ti. or 54910 89 3.rn.
6	exp fluvoxamine/ or fluvoxamine.tn,ab,ti. or 54739 18 3.rn.
7	exp milnacipran/ or levomilnacipran.tn,ab,ti. or 96847 54 0.rn.
8	exp mirtazapine/ or mirtazapine.tn,ab,ti. or 85650 52 8.rn.
9	exp nefazodone/ or nefazodone.tn,ab,ti. or 82752 99 6.rn.
10	exp paroxetine/ or paroxetine.tn,ab,ti. or 61869 08 7.rn.
11	exp sertraline/ or sertraline.tn,ab,ti. or 79617 96 2.rn.
12	exp trazodone/ or trazodone.tn,ab,ti. or 19794 93 5.rn.
13	exp venlafaxine/ or venlafaxine.tn,ab,ti. or 93413 69 5.rn.
14	exp vilazodone/ or vilazodone.tn,ab,ti. or 163521 12 8.rn.
15	exp vortioxetine/ or vortioxetine.tn,ab,ti. or 508233 74 7.rn.
16	exp duloxetine/ or duloxetine.tn,ab,ti. or 116539 59 4.rn.
17	exp antidepressant agent/ or antidepress*.ti,ab.
18	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19	exp depression/ or exp major depression/ or depress*.ab,ti,kw.
20	exp randomized controlled trial/ or randomized controlled trial.ab,ti,pt. or randomized
	placebo trial.ti,ab. or exp randomization/
21	18 and 19 and 20
22	exp exercise/ or exercise.ti,ab. or aerobic.ti,ab. or training.ti,ab. or lift*.ti,ab. or
	running.ti,ab. or jogging.ti,ab. or walk*.ti,ab. or swim*.ti,ab. or cycl*.ti,ab.
23	19 and 20 and 22
24	exp adults/ or adult*.ti,ab.
25	21 and 24
26	23 and 24
27	25 or 26
28	Limit 27 to yr=1990-Current, English, Chinese, Italian language

Scopus

#	Query
#1	TITLE-ABS-KEY(bupropion OR citalopram OR escitalopram OR desvenlafaxine OR
	fluoxetine OR fluvoxamine OR milnacipran OR mirtazapine OR nefazodone OR

	paroxetine OR sertraline OR trazodone OR venlafaxine OR vilazodone OR
	vortioxetine OR duloxetine OR antidepress*)
#2	TITLE-ABS-KEY(depress*)
#3	TITLE-ABS-KEY(randomized controlled trial)
#4	TITLE-ABS-KEY(adult*)
#5	#1 AND #2 AND #3 AND #4
#6	TITLE-ABS-KEY(exercise OR 'physical activity' OR aerobic OR training OR lift* OR
	running OR walk* OR jogging OR swim* OR cycl*)
#7	#2 AND #3 AND #4 AND #6
#8	#5 OR #7

SportDiscus

Search	Query
S1	(TI(bupropion OR citalopram OR escitalopram OR desvenlafaxine OR fluoxetine OR fluvoxamine OR milnacipran OR mirtazapine OR nefazodone OR paroxetine OR sertraline OR trazodone OR venlafaxine OR vilazodone OR vortioxetine OR duloxetine OR antidepress*)) OR (AB(bupropion OR citalopram OR escitalopram OR desvenlafaxine OR fluoxetine OR fluvoxamine OR milnacipran OR mirtazapine OR nefazodone OR paroxetine OR sertraline OR trazodone OR venlafaxine OR vilazodone OR vortioxetine OR duloxetine OR antidepress*)) OR (SU(bupropion OR citalopram OR escitalopram OR desvenlafaxine OR fluvoxamine OR milnacipran OR mirtazapine OR nefazodone OR paroxetine OR sertraline OR trazodone OR venlafaxine OR vilazodone OR paroxetine OR sertraline OR antidepress*))
S2	SU(depression or depressive disorder or depressive symptoms or major depressive disorder) OR TI depress* OR AB depress*
S3	SU(randomized controlled trials or rtc or randomised control trials) OR TI(random* AND control*) OR AB (random* AND control*)
S4	SU(adults or adult) OR TI adult* OR AB adult*
S5	S1 AND S2 AND S3 AND S4
S6	SU(exercise or physical activity) OR TI(exercise OR 'physical activity' OR aerobic OR training OR lift* OR running OR walk* OR jogging OR swim* OR cycl*) OR AB(exercise OR 'physical activity' OR aerobic OR training OR lift* OR running OR walk* OR jogging OR swim* OR cycl*)
S7	S2 AND S3 AND S4 AND S6
S8	S5 OR S7

Web of Science

#	Query
#1	TS=(bupropion OR citalopram OR escitalopram OR desvenlafaxine OR fluoxetine OR fluvoxamine OR milnacipran OR mirtazapine OR nefazodone OR paroxetine OR sertraline OR trazodone OR venlafaxine OR vilazodone OR vortioxetine OR duloxetine OR antidepress*)
#2	TS=(depress*)
#3	TS=(random* AND (control* OR placebo))
#4	TS=(adult*)
#5	TS=(exercise OR 'physical activity' OR aerobic OR training OR lift* OR running OR walk* OR jogging OR swim* OR cycl*)
#6	#1 AND #2 AND #3 AND #4
#7	#2 AND #3 AND #4 AND #5
#8	#6 OR #7

eAppendix 2. Additional methodology information

Risk of bias

The Cochrane risk of bias assessment tool (RoB-2) was used to determine the quality of the individual studies.¹ Bias was assessed in the following domains: 1) randomization process, 2) deviations from the intended interventions, 3) missing outcome data, 4) measurement of the outcome, and 5) selection of the reported results. Each domain was assessed as having either low risk of bias, some concerns, or high risk of bias.

To implement RoB-2, we utilized the Excel template provided in the "Cochrane Handbook for Systematic Reviews of Interventions",² which includes "signalling questions" that can be used to assess bias in each domain. Each domain is automatically evaluated by an algorithm based on the signalling questions, as well as subjectively by the author. To avoid the influence of personal bias, the assessment of each domain was strictly based on the output of the algorithm.

- 1. Bias due to the randomization process was rated "low" if the study allocation sequence was reported as random and there was evidence that the allocation sequence was concealed. Allocation concealment was considered adequate if the allocation was carried out by investigators that were external to the project, or if authors used a form of remote or centrally administered method that ensured allocation concealment (e.g., sealed opaque envelopes). If the strategy for allocation concealment was not clearly reported, the domain was rated as having "some concerns". If both categories were deemed to be inadequately described, the domain was rated "high".
- 2. Bias due to deviations from the intended interventions was based on whether participants and/or study personnel were blinded to participants' assigned intervention, whether there were deviations from the intervention due to the trial context, and whether an appropriate analysis was used to estimate the effect of the intervention. Bias was rated "low" if all categories were rated as low. Following the Cochrane algorithm, if participants or study personnel were aware of participants' allocated intervention but all other categories were considered as low, the domain was still rated as "low". If there were deviations from the interventions that were suspected to affect the outcome, and if these were not balanced between groups, or if an inappropriate statistical analysis was used that was suspected to substantially impact the outcome, the domain was rated "high". Any other combination was rated as having "some concerns".
- 3. Bias due to missing outcome data was rated "low" if data were available for all, or nearly all, participants randomized. If there was the possibility that missingness in the outcome was influenced by its true value, the domain was rated "some concerns". If missingness in the outcome was likely influenced by its true value, the domain was rated "high".
- 4. Bias in measurement of the outcome was rated "high" if the method for measuring the outcome was inappropriate, if it differed between groups, or if it was likely that the assessment was influenced by knowledge of the intervention. It was rated "some concerns" if outcome assessors were aware of the intervention received by participants, but it was not likely that assignment was influenced by knowledge of the intervention. Bias in measurement of the outcome was rated "low" if all categories were considered as low.
- 5. Bias in selection of the reported result was rated "low" if it was unlikely that the results were selected from multiple measurements or analyses, and data were analysed in accordance with a pre-specified plan. If no pre-specified plan was available but it was unlikely that results were selected from multiple measurements or analyses, the domain was rated "some concerns". If it was suspected that results were selected from multiple measurements or analyses, the domain was rated "high".

Overall risk of bias was rated "low" if all domains were rated "low", it was rated "some concerns" if the study was judged to raise some concerns in at least one domain, but not to be at high risk of bias for any domain, and it was was rated "high" if at least one domain was considered as "high".

Confidence of Network Meta-analysis (CINeMA) rating

We used the CINeMA framework to assess the overall credibility of the results.³ CINeMA is based on the following domains: 1) within-study bias, 2) reporting bias, 3) indirectness, 4) imprecision, 5) heterogeneity, and 6) incoherence. Within-study bias was evaluated using the RoB-2 tool. Reporting bias for each comparison was coded as "suspected" or "undetected" based on the completeness of the research and availability of published data. Indirectness was assessed as described below. To assess imprecision, heterogeneity, and incoherence, we set the clinically significant effect size to 0.35.⁴

Indirectness

Indirectness was assessed based on recommended guidelines.⁵ We evaluated whether studies differed in relation to 1) population, 2) intervention, 3) outcome, and 4) whether a study showed direct evidence for at least one comparison of interest. Study indirectness was coded as "low" if three or more outcomes were considered to be "low" and no more than one was "unclear", and coded as "high" if two or more outcomes were considered to be "high", whereas any other combination was coded as "moderate".

- 1. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:I4898.
- Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
- 3. Nikolakopoulou A, Higgins JPT, Papakonstantinou T, et al. CINeMA: An approach for assessing confidence in the results of a network meta-analysis. *PLOS Medicine*. 2020;17(4):e1003082.
- 4. Kroenke K, Stump TE, Chen CX, et al. Minimally important differences and severity thresholds are estimated for the PROMIS depression scales from three randomized clinical trials. *Journal of affective disorders*. 2020;266:100-108. doi:10.1016/j.jad.2020.01.101
- 5. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. Rating the quality of evidenceindirectness. *Journal of Clinical Epidemiology*. 2011;64(12):1303-1310.

eAppendix 3. Pairwise meta-analyses

Comparative effectiveness on depressive symptoms from pairwise meta-analyses

Study	Exercis Total Mean S	e Antidepressants) Total Mean SD	Standardised Mean Difference	SMD 95%-CI
Blumenthal(2007) Hidalgo(2021) Blumenthal(1999)	51 9.20 6.692 176 5.35 5.130 53 8.10 6.541	0 171 5.85 4.5400		-0.15 [-0.54; 0.24] -0.10 [-0.31; 0.11] 0.05 [-0.34; 0.44]
Random effects model Heterogeneity: $I^2 = 0\%$, τ^2		268	-0.4 -0.2 0 0.2 0.4	-0.08 [-0.29; 0.12]

	Exer	se Co	ontrol Standardised Mean	
Study	Total Mean	SD Total Mean	SD Difference	SMD 95%-CI
Dunn(2005)	17 9.00 3.6			-1.16 [-1.94; -0.37]
McNeil(1991)	10 11.10 3.0			-1.02 [-1.97; -0.08]
Hemat-Far(2012)	10 16.60 6.9	00 10 22.80 4.	9000	-0.99 [-1.93; -0.05]
Sadeghi (2016)	16 13.31 5.4	00 14 18.35 6.	1400	-0.85 [-1.61; -0.10]
Blumenthal(2007)	51 9.20 6.6	25 49 11.00 6.	7180	-0.27 [-0.66; 0.13]
Krogh(2012)	56 11.30 6.6	00 59 10.50 6.	4000 -	0.12 [-0.24, 0.49]
Random effects mode Heterogeneity: $I^2 = 69\%$,		155		-0.58 [-1.14; -0.01]
			-1 0 1	

	An	tidepressants			Control	Standardised Mean		
Study	Total	Mean SE	Total	Mean	SD	Difference	SMD	95%-CI
Moreno(2006)	20	6.70 3.9916			5.0154			[-1.49; -0.26]
Detke(2004)	93	8.10 5.7500			5.6200			[-0.82; -0.23]
Goldstein(2004)	86	9.30 5.7500	89	12.20	5.6200		-0.51	[-0.81; -0.21]
Philipp(1999)	105	8.00 5.7500	46	10.60	5.6200	· · · · · ·	-0.45	[-0.80; -0.10]
Gastpar(2006)	127	10.30 6.4000	130	13.00	6.9000		-0.40	[-0.65; -0.16]
Detke(2002)	128	9.90 5.7500	139	12.20	5.6200		-0.40	[-0.65; -0.16]
Mao(2015)	19	7.90 2.6820	18	8.60	3.1095		-0.24	[-0.88; 0.41]
Perahia(2006)	102	9.00 5.7500	99	9.80	5.6200		-0.14	[-0.42; 0.14]
Blumenthal(2007)	49	10.20 6.6389	49	11.00	6.7180		-0.12	[-0.52; 0.28]
Bjerkenstedt(2005)	54	14.90 8.4000	55	15.50	6.7000		-0.08	[-0.45; 0.30]
Fava(2005)	47	13.30 7.3000	43	12.60	6.4000		0.10	[-0.31; 0.51]
Random effects mode Heterogeneity: $I^2 = 38\%$.			787				-0.33	[-0.49; -0.16]
	0.01	, p 0.10				-1 -0.5 0 0.5 1		

Study	Combinatio Total Mean S	n Antidepressants D Total Mean SD	Standardised Mean Difference	SMD 95%-CI
Danielsson(2014) Siqueira(2016) Mather(2002) Blumenthal(1999)	22 14.00 8.417 29 11.38 3.940 43 12.60 6.505 55 9.30 7.034	28 12.64 5.7400 43 13.70 6.5054		-0.52[-1.14; 0.09]-0.25[-0.77; 0.27]-0.17[-0.59; 0.26]0.23[-0.16; 0.62]
Random effects model Heterogeneity: $I^2 = 41\%$, τ^2		139	-1 -0.5 0 0.5	-0.13 [-0.63; 0.36]

		Comb	ination		E	rcise	S	tanda	rdise	d Mea	n		
Study	Total	Mean	SD	Total	Mean	SD		Dif	ferer	nce		SMD	95%-CI
Blumenthal(1999)	55	9.30	7.0342	53	8.10	6.5419	-0.4	-0.2	0	0.2		- 0.18	[-0.2; 0.55]

Comparative effectiveness on acceptability from pairwise meta-analyses

		EX		AD			
Study	Events	Total Ev	ents To	otal	Risk Ratio	RR	95%-CI
Hidalgo(2021) Blumenthal(2007)	110 10	176 51	78 1 7	171 49			[1.12; 1.67]
Blumenthal(1999)	14	53	7	49			[0.80; 4.11]
Random effects mode	el	280	2	268		1.40	[1.13; 1.72]
Heterogeneity: $I^2 = 0\%$, τ	² = 0.0031,	p = 0.81			0.5 1 2		
					0.0		
		EX	C	ст			
Study	Events	Total Eve	ents Tot	tal	Risk Ratio	RR	95%-CI
Dunn(2005)	7	17		13 -			[0.33; 1.36]
Blumenthal(2007) Krogh(2012)	10 9	51 56		49 - 59			[0.34; 1.40] [0.60; 4.15]
Random effects mode		124	1	21		0.84	[0.27; 2.58]
Heterogeneity: $I^2 = 14\%$, τ							[0.2.7, 2.00]
					0.5 1 2		
Study	Events	AD Total Ev		CT	Risk Ratio	RR	95%-CI
Blumenthal(2007)	7	49		49	1		
Detke(2004)	4	93	6	93			[0.22; 1.13] [0.19; 2.29]
Mao(2015)	4	20		26			[0.25; 2.19]
Moreno(2006) Gastpar(2006)	23		115 March 116	26 30		0.74	[0.25; 2.19] [0.57; 1.57]
Fava(2005)	23	47		43		0.96	[0.63; 1.45]
Goldstein(2004)	38	91		89	+		[0.71; 1.42]
Detke(2002) Bjerkenstedt(2005)	50 20	128 57		139 58			[0.81; 1.51] [0.67; 1.90]
Philipp(1999)	1			47 -		- 1.29 [0.05; 31.09]
Perahia(2006)	13	103	9	99		1.39	[0.62; 3.10]
Random effects mod		845	7	99		0.97	0.84; 1.13]
Heterogeneity: $I^2 = 0\%$, 1	² = 0.0273,	p = 0.88		0	0.1 0.5 1 2 10		
	(Comb		AD			
Study		Total Eve			Risk Ratio	RR	95%-CI
Danielsson(2014)	4	22		20 —			[0.20; 1.84]
Siqueira(2016) Blumenthal(1999)	9 11	29 55		28 48			[0.49; 2.41] [0.58; 3.26]
Random effects mode		106					
Heterogeneity: $I^2 = 0\%$, τ				96	1 1 1		[0.40; 2.65]
				0.2	0.5 1 2	5	
Study Ev	Com ents Tota		EX Total		Risk Ratio	RR	95%-CI
Blumenthal(1999)	11 5	5 14	53			0.76 [0).38; 1.52]
				0.5	1 2		

20

Recchia F, et al. Br J Sports Med 2022;0:1-7. doi: 10.1136/bjsports-2022-105964

eAppendix 4. References

Bjerkenstedt L, Edman GV, Alken RG, Mannel M. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. *European archives of psychiatry and clinical neuroscience*. Feb 2005;255(1):40-7. doi:10.1007/s00406-004-0532-z

Blumenthal J, Babyak M, Moore K, et al. Effects of Exercise Training on Older Patients With Major Depression. *Archives of internal medicine*. 10/01 1999;159:2349-56. doi:10.1001/archinte.159.19.2349

Blumenthal JA, Babyak MA, Doraiswamy PM, et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. *Psychosom Med.* Sep-Oct 2007;69(7):587-96. doi:10.1097/PSY.0b013e318148c19a

Danielsson L, Papoulias I, Petersson EL, Carlsson J, Waern M. Exercise or basic body awareness therapy as add-on treatment for major depression: a controlled study. *Journal of affective disorders*. Oct 2014;168:98-106. doi:10.1016/j.jad.2014.06.049

Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. *Journal of psychiatric research*. Nov-Dec 2002;36(6):383-90. doi:10.1016/s0022-3956(02)00060-2

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology*. Dec 2004;14(6):457-70. doi:10.1016/j.euroneuro.2004.01.002

Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO. Exercise treatment for depression: Efficacy and dose response. *American journal of preventive medicine*. January 2005;28(1):1-8

Fava M, Alpert J, Nierenberg AA, et al. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. *Journal of clinical psychopharmacology*. Oct 2005;25(5):441-7. doi:10.1097/01.jcp.0000178416.60426.29

Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: A doubleblind, randomised, multicentre, placebo-controlled study. *Pharmacopsychiatry*. March 2006;39(2):66-75

Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. *Journal of clinical psychopharmacology*. Aug 2004;24(4):389-99. doi:10.1097/01.jcp.0000132448.65972.d9

Hemat-Far A, Shahsavari A, Mousavi SR. Effects of selected aerobic exercises on the depression and concentrations of plasma serotonin in the depressed female students aged 18 to 25. *Journal of Applied Research*. 2012;12(1):47-52

Hidalgo JL-T, Sotos JR, Group D-E. Effectiveness of Physical Exercise in Older Adults With Mild to Moderate Depression. *The Annals of Family Medicine*. 2021;19(4):302-309. doi:10.1370/afm.2670

Krogh J, Videbech P, Thomsen C, Gluud C, Nordentoft M. DEMO-II Trial. Aerobic Exercise versus Stretching Exercise in Patients with Major Depression-A Randomised Clinical Trial. *PLoS One.* 31 Oct 2012;7 (10) (e48316)

Mao JJ, Xie SX, Zee J, et al. Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial. *Phytomedicine : international journal of phytotherapy and phytopharmacology*. Mar 15 2015;22(3):394-9. doi:10.1016/j.phymed.2015.01.010

Mather AS, Rodriguez C, Guthrie MF, McHarg AM, Reid IC, McMurdo MET. Effects of exercise on depressive symptoms in older adults with poorly responsive depressive disorder. *British Journal of Psychiatry*. 2002;180(MAY):411-415

McNeil JK, LeBlanc EM, Joyner M. The effect of exercise on depressive symptoms in the moderately depressed elderly. *Psychology and aging*. Sep 1991;6(3):487-8. doi:10.1037//0882-7974.6.3.487

Moreno RA, Teng CT, Almeida KM, Tavares Junior H. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample. *Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)*. Mar 2006;28(1):29-32. doi:10.1590/s1516-44462006000100007

Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. *European psychiatry : the journal of the Association of European Psychiatrists*. Sep 2006;21(6):367-78. doi:10.1016/j.eurpsy.2006.03.004

Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: Randomised multicentre study of treatment for eight weeks. *British Medical Journal*. 11 Dec 1999;319(7224):1534-1538

Sadeghi K, Ahmadi SM, Ahmadi SM, et al. A Comparative Study of the Efficacy of Cognitive Group Therapy and Aerobic Exercise in the Treatment of Depression among the Students. *Global journal of health science*. Oct 1 2016;8(10):54171. doi:10.5539/gjhs.v8n10p1

Siqueira CC, Valiengo LL, Carvalho AF, et al. Antidepressant Efficacy of Adjunctive Aerobic Activity and Associated Biomarkers in Major Depression: A 4-Week, Randomized, Single-Blind, Controlled Clinical Trial. *PLoS One*. 2016;11(5):e0154195 doi:10.1371/journal.pone.0154195